Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Managing Ocular Pain and Inflammation After Cataract Surgery – Part 1

By: John Sheppard, MD, MMSc, moderator; Johnny Gayton, MD; John Wittpenn, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

This continuing medical education (CME) activity captures content from a live symposium held in October of 2016 in Chicago, Illinois.

This certified CME activity is designed for ophthalmologists involved in the comanagement of postoperative cataract patients.

Expiration Date: Wednesday, January 31, 2018
Release Date: January 2017

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the pharmacokinetic properties of the bromfenac molecule
  • Assess the ability of topical ophthalmic NSAIDs to treat postoperative inflammation and pain in a cataract patient
  • Analyze the safety profile of the bromfenac molecule
  • Discuss the obstacles patients face in compliance and adherence
  • Develop a plan to communicate compliance obstacles with patients

Accreditation and Designation Statement

ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty members have the following financial relationships with commercial interests:

John Sheppard, MD, MMSc, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: 1-800-Doctors; AbbieVie; Alcon; Aldeyra; Allergan; ArcScan; Bausch + Lomb; Bio-Tissue; Clearside; Clearview; Eleven/Lexitas; EyeGate Research; Hovione; Imprimis Pharma; Inspire/Merck Pharmaceuticals; Isis Pharmaceuticals; Kala Pharmaceuticals; Lacrisciences; Lenstatin; LayerBio; Lumenis; Lux Biosciences; NiCox; NovaBay; Novartis/CibaVision; OcuCure; Oculeve; Ocular Therapeutics; Omeros; Pentavision; Pfizer; Portage; Rapid Pathogen Screening; Santen Pharmaceuticals; Science Based Health; Shire/SarCode Biosciences; Sjo/Nicox; Stemnion; Sun Pharmaceuticals; Synedegen; Talia Technology; TearLab; TearScience; Topivert; and Vistakon. Contracted Research: Alcon; Aldeyra; Allergan; ArcScan; Bausch + Lomb; Clearview; EyeGate Research; EyeRx Research; InSite Vision; Inspire/Merck Pharmaceuticals; Isis Pharmaceuticals; Kala Pharmaceuticals; Lux Biosciences; Oculeve; Ocular Therapeutics; Pfizer; Rapid Pathogen Screening; Rutech; Santen Pharmaceuticals; Senju; Shire/SarCode Biosciences; TearScience; Vistakon; and Xoma/Servier. Stock/Shareholder: 1-800-Doctors; Alphaeon; BioLayer; Clearside; EyeGate Research; EyeRx Research; Lacrisciences; Lumenis; NovaBay; Occuhub; OcuCare; Rapid Pathogen Screening; Shire/SarCode Biosciences; Stemnion; Strathspey Crowne; and TearLab.

Johnny Gayton, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Abbott Medical Optics; Bausch + Lomb; Omerus; ScienceBased Health; Shire; and Sun Pharmaceutical Industries Ltd.

John Wittpenn, MD, has had no financial agreements or affiliations during the past year.

EDITORIAL SUPPORT DISCLOSURES
Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; and Michelle Dalton, medical writer, have no financial relationships with commercial interests.

Rishi Singh, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech; and Regeneron Pharmaceuticals.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, Advanced Ocular Care, Cataract & Refractive Surgery Today, or Sun Pharmaceutical Industries Ltd.

Managing Ocular Pain and Inflammation After Cataract Surgery: Differentiating Among the Nonsteroidal Antiinflammatory Drugs (Part 1)

John Sheppard, MD, MMSc, moderator; Johnny Gayton, MD; John Wittpenn, MD

BackNext